## Statement of Equity, Peptinovo Biopharma Inc. 2023, 2024

Equity	2023			
	2023	Beginning	change	ending
Common stock beginning balance Warrants exercised for common stock Common stock ending balance		9,917	450	10,367
Retained earnings Net loss Earnings		(1,075,883)	(2,832,690)	(3,908,572)
SAFE investment agreements beginning Additional SAFE investments SAFE investments ending balance		1,878,158	123,700	2,001,858
	2023	812,192	(2,708,540)	(1,896,347)
	2024	Destructions	ali an da	a sa alisa ar
Common stock beginning balance		Beginning 10,367	change	ending
Purchase of common stock (Brown)  Exercise of options for common stock			3,200 13,544	07.444
Common stock ending balance				27,111
Retained earnings Net loss Earnings		(3,908,572)	(4,803,155)	(8,711,727)
SAFE investment agreements beginning Converted to Series A preferred shares SAFE investments ending balance		2,001,858	(2,001,858)	-
Series A peferred shares		-	2.755.000	
Conversion of convertible debt notes Conversion of SAFE notes			3,755,900 2,001,858	
New purchases of Series A preferred shares Series A peferred shares ending balance			2,558,700	8,316,458
	2024	(1,896,347)	1,528,189	(368,158)